NYSE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Qiagen N.v. QGEN
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.1B
▲ 5.7% vs FY2024
EPS · FY25
$1.94
Dividend / sh · FY25
$0.25
Payout · FY25
13%
ROE · FY25
11.6%
Net margin · FY25
20.3%
Dividend coverage
7.8×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.1B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
20 cents of every revenue dollar became profit this year.
Per share
USD 1.94
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 7.8 times — the rest stayed in the company.
Profitability
11.6%
Return on equity, FY2025
ROE
Operating margin22.3%
Net margin20.3%
Return on assets7.1%
Each USD of equity produced 12 cents of profit this year.
Returned to shareholders
USD 334.3M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 54.2M
Net buybacksUSD 280.1M
Share of profit78.7%
Consecutive raises—
USD 54.2M in dividends and USD 280.1M in buybacks — 79% of the year's profit went back to shareholders.
Growth
+2.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.8%
+2.2%
+5.0%
+4.5%
Net income
+0.1%
+3.4%
+12.6%
+7.5%
EPS, diluted
+1.8%
+4.9%
+13.4%
Returned to shareholders
+42.8%
+41.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 6.3B
total assets, end of FY2025
Total assetsUSD 6.3B
EquityUSD 3.8B
CashUSD 839.0M
Gross debtUSD 1.7B
Net debtUSD 815.4M
Current ratio3.90×
Net debt stands at 22% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
2.1
2.0
2.0
2.1
2.3
1.9
1.5
1.5
1.4
1.3
1.3
1.3
1.3
1.3
1.2
1.1
1.0
0.9
Operating income $B
0.5
0.1
0.4
0.5
0.6
0.4
−0.0
0.3
0.2
0.1
0.2
0.2
0.1
0.2
0.1
0.2
0.2
0.1
EBITDA $B
0.7
0.3
0.6
0.7
0.8
0.6
0.2
0.5
0.4
0.3
0.4
0.4
0.3
0.4
0.3
0.3
0.2
0.2
Income tax $B
0.1
0.0
0.1
0.1
0.1
0.1
−0.0
0.0
0.1
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.4
0.1
0.3
0.4
0.5
0.4
−0.0
0.2
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
EPS, diluted $
1.94
0.37
1.48
1.84
2.21
1.53
−0.18
0.82
0.17
0.34
0.55
0.48
0.29
0.54
0.40
0.60
0.64
0.44
Dividend / sh $
0.25
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
13
0
0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
11.6
2.3
9.4
12.9
17.4
13.5
−1.6
7.4
1.6
3.1
5.0
4.3
2.5
4.9
3.8
5.8
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
0.24
0.23
0.00
0.23
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
70 of 70
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed